Literature DB >> 122411

Clinical and endocrinological analyses of patients with galactorrhea and menstrual disorders due to sulpiride or metoclopramide.

T Aono, T Shioji, T Kinugasa, T Onishi, K Kurachi.   

Abstract

The clinical courses of galactorrhea and menstrual disorders were studied in 18 women with galactorrhea induced by sulpiride (SLP) or metoclopramide (MCP) given for the treatment of gastrointestinal diseases. The response of PRL and TSH to 500 micrograms iv TRH and the response of LH and FSH to 100 micrograms LRH were assessed by retrospective analysis during treatment in nine patients (six, SLP; three, MCP) and shortly after the end of treatment in nine patients (seven, SLP; two, MCP). The average time from the initiation of treatment to the onset of galactorrhea was 27.2 +/- 4.7 (mean +/- SE) days in the 13 SLP-treated patients and 23.2 +/- 5.8 days in the 5 MCP-treated patients. Five of the SLP-treated patients experienced amenorrhea, four had oligomenorrhea, and one had dysfunctional bleeding. In the MCP-treated patients, oligomenorrhea and dysfunctional bleeding occurred in one each. The average length of time from the end of treatment to disappearance of galactorrhea was 50.0 +/- 7.3 days in the SLP-treated patients and 56.6 +/- 12.1 days in the MCP-treated patients. Cyclic uterine bleeding returned within 2 months after treatment was stopped. Elevated PRL levels with good response to TRH were observed in four of six patients during SLP treatment, and in two of three patients during MCP treatment. Basal PRL levels and response to TRH were normal in almost all patients after the drugs were withdrawn. Normal HL and FSH levels with exaggerated responses of LH to LRH were observed in most patients during treatment, whereas the response of LH to LRH was normal in about half of the patients after treatment. Our findings suggest that hyperprolactinemia in patients treated with SLP or MCP may be in part the cause of both galactorrhea and menstrual abnormalities, and that these symptoms can be reversed by stopping treatment, provided the patients have not taken the drugs for longer than a year.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 122411     DOI: 10.1210/jcem-47-3-675

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Metoclopramide-induced reversible impotence.

Authors:  R G Berlin
Journal:  West J Med       Date:  1986-03

2.  Diagnostic value of thyrotropin-releasing-hormone stimulation in patients with pituitary tumor.

Authors:  D M Cook; M A Greer; H Paxton
Journal:  West J Med       Date:  1987-08

3.  Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine.

Authors:  R M Carey; M O Thorner; E M Ortt
Journal:  J Clin Invest       Date:  1980-07       Impact factor: 14.808

Review 4.  Drugs and prolactin.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

5.  Immunocytochemical evidence for the ability of the human pharyngeal hypophysis to respond to change in endocrine feedback.

Authors:  D R Ciocca; L A Puy; A O Stati
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

Review 6.  Metoclopramide. An updated review of its pharmacological properties and clinical use.

Authors:  R A Harrington; C W Hamilton; R N Brogden; J A Linkewich; J A Romankiewicz; R C Heel
Journal:  Drugs       Date:  1983-05       Impact factor: 9.546

7.  Etiological Profile of Galactorrhoea.

Authors:  Sridevi Atluri; Vijaya Sarathi; Amit Goel; Rakesh Boppana; C Shivaprasad
Journal:  Indian J Endocrinol Metab       Date:  2018 Jul-Aug

8.  Omeprazole-induced galactorrhea in kidney transplant patients-a case report.

Authors:  Choki Dorji; Farruk Ahammed Robin; Kesara Na-Bangchang
Journal:  J Med Case Rep       Date:  2022-03-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.